Wakefield, United States
Ablative Solutions is a clinical-stage medical device startup founded in 2011 and headquartered in the United States. The company is focused on pioneering the novel approach of Transcatheter Perivascular Alcohol Denervation for the treatment of hypertension, which affects over one billion people worldwide and an estimated 67 million in the United States alone. The innovative Peregrine System developed by Ablative Solutions uses alcohol as the neurolytic agent to disrupt sympathetic nerves, with potential advantages over energy-based systems.
The company's Peregrine System Infusion Catheter has received FDA 510(k) clearance for the infusion of diagnostic and therapeutic agents into the perivascular area of the peripheral vasculature and also obtained the CE Certificate of Conformity in Europe for the treatment of hypertensive patients. Currently, Ablative Solutions is conducting a post-market clinical study in Europe and planning a randomized clinical trial in the United States to seek approval for the system's use in the treatment of hypertension.
The most recent investment in Ablative Solutions was a $91.40M Series D investment on 13 June 2022, led by Gilde Healthcare, Invus, and BioStar Capital.
Through its pioneering medical device technology and ongoing clinical trials, Ablative Solutions is poised to make a significant impact in the biotechnology and healthcare industries by addressing the critical global health issue of hypertension.
